Optimising patient outcomes in myeloma.

摘要: Multiple myeloma (MM) is an incurable disease, and the goal of therapy to prolong survival. Newer therapies (thalidomide, lenalidomide, bortezomib) have contributed recent improvements in Optimal integration these newer into standard practice may be aided by better methods risk stratification. Supplementation existing stratification with new prognostic information, such as cytogenetic data gene expression profiles, improve prognostication help identify appropriate treatment. The advent has also prompted a reassessment traditional endpoints goals therapy, complete response. While response correlates survival some cases, correlation not consistent across all treatment regimens patient groups, therefore always most therapy. With aim prolonging survival, trials are currently evaluating long-term maintenance or prevention for patients smouldering myeloma. Given that often asymptomatic free clinically active success this setting depends highly on tolerability agents. available evidence suggests their adverse event profiles distinct, predictable, manageable careful monitoring intervention appropriate. Treatment MM should tailored individual based condition, expected events, preference.